Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms

Oncogene

Volumn 32, Issue 36, 2013, Pages 4273-4283

  Deng, M ^a,b,c   Zhang, W ^a   Tang, H ^a,b   Ye, Q ^a   Liao, Q ^a,b   Zhou, Y ^a   Wu, M ^a   Xiong, W ^a   Zheng, Y ^a   Guo, X ^a   Qin, Z ^a   He, W ^a   Zhou, M ^a   Xiang, J ^a   Li, X ^a   Ma, J ^a   Li, G ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

14 3 3; AKT; keratin 18; LTF; nasopharyngeal carcinoma; PDK1

Indexed keywords

CYTOKERATIN 18; LACTOFERRIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN C JUN; PROTEIN KINASE B;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; COMPLEX FORMATION; DOWN REGULATION; METASTASIS; MOUTH MUCOSA; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

14-3-3 PROTEINS; ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; EXONUCLEASES; FEMALE; GENE EXPRESSION; HUMANS; LACTOFERRIN; MALE; MICE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84883742239     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.434     Document Type: Article

References (44)

1. Montreuil J, Tonnelat J, Mullet S. Preparation and properties of lactosiderophilin (lactotransferrin) of human milk. Biochim Biophys Acta 1960; 45: 413-421.
2. Ward PP, Paz E, Conneely OM. Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci 2005; 62: 2540-2548.
3. Gonzalez-Chavez SA, Arevalo-Gallegos S, Rascon-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents 2009; 33: e1-e8.
4. Sekine K, Watanabe E, Nakamura J, Takasuka N, Kim DJ, Asamoto M et al. Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res 1997; 88: 523-526.
5. Tsuda H, Sekine K, Nakamura J, Ushida Y, Kuhara T, Takasuka N et al. Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Adv Exp Med Biol 1998; 443: 273-284.
6. Matsuda Y, Saoo K, Hosokawa K, Yamakawa K, Yokohira M, Zeng Y et al. Postinitiation chemopreventive effects of dietary bovine lactoferrin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in female A/J mice. Cancer Lett 2007; 246: 41-46.
7. Varadhachary A, Wolf JS, Petrak K, O'Malley Jr BW, Spadaro M, Curcio C et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 2004; 111: 398-403.
8. Bezault J, Bhimani R, Wiprovnick J, Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res 1994; 54: 2310-2312.
9. Li WY, Li QW, Han ZS, Jiang ZL, Yang H, Li J et al. Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm 2011; 26: 477-483.
10. Yi HM, Li H, Peng D, Zhang HJ, Wang L, Zhao M et al. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. Oncol Res 2006; 16: 261-272.
11. Campbell T, Skilton RA, Coombes RC, Shousha S, Graham MD, Luqmani YA. Isolation of a lactoferrin cDNA clone and its expression in human breast cancer. Br J Cancer 1992; 65: 19-26.
12. Kholodnyuk ID, Kozireva S, Kost-Alimova M, Kashuba V, Klein G, Imreh S. Down regulation of 3p genes, LTF, SLC38A3 and DRR1, upon growth of human chromosome 3-mouse fibrosarcoma hybrids in severe combined immunodeficiency mice. Int J Cancer 2006; 119: 99-107.
13. Yang Y, Li J, Szeles A, Imreh MP, Kost-Alimova M, Kiss H et al. Consistent downregulation of human lactoferrin gene, in the common eliminated region 1 on 3p21.3, following tumor growth in severe combined immunodeficient (SCID) mice. Cancer Lett 2003; 191: 155-164.
14. Xiao Y, Monitto CL, Minhas KM, Sidransky D. Lactoferrin down-regulates G1 cyclindependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res 2004; 10: 8683-8686.
15. Damiens E, El Yazidi I, Mazurier J, Duthille I, Spik G, Boilly-Marer Y. Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem 1999; 74: 486-498.
16. Son HJ, Lee SH, Choi SY. Human lactoferrin controls the level of retinoblastoma protein and its activity. Biochem Cell Biol 2006; 84: 345-350.
17. Wu M, Li X, Li G. Signaling transduction network mediated by tumor suppressor/susceptibility genes in NPC. Curr Genomics 2009; 10: 216-222.
18. Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, Tan Y et al. Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogenactivated protein kinase pathway. Int J Cancer 2008; 123: 2065-2072.
19. Kikani CK, Dong LQ, Liu F. 'New'-clear functions of PDK1: beyond a master kinase in the cytosol? J Cell Biochem 2005; 96: 1157-1162.
20. Bayascas JR. Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways. Cell Cycle 2008; 7: 2978-2982.
21. Mariller C, Benaissa M, Hardiville S, Breton M, Pradelle G, Mazurier J et al. Human delta-lactoferrin is a transcription factor that enhances Skp1 (S-phase kinaseassociated protein) gene expression. FEBS J 2007; 274: 2038-2053.
22. Lopez-Bergami P, Kim H, Dewing A, Goydos J, Aaronson S, Ronai Z. c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis. J Biol Chem 2010; 285: 903-913.
23. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7: 261-269.
24. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
25. Wick MJ, Dong LQ, Riojas RA, Ramos FJ, Liu F. Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1. J Biol Chem 2000; 275: 40400-40406.
26. Omary MB, Ku NO, Strnad P, Hanada S. Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest 2009; 119: 1794-1805.
27. Trask DK, Band V, Zajchowski DA, Yaswen P, Suh T, Sager R. Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc Natl Acad Sci USA 1990; 87: 2319-2323.
28. Kim S, Wong P, Coulombe PA. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature 2006; 441: 362-365.
29. Liao J, Omary MB. 14-3-3 proteins associate with phosphorylated simple epithelial keratins during cell cycle progression and act as a solubility cofactor. J Cell Biol 1996; 133: 345-357.
30. Ku NO, Michie S, Resurreccion EZ, Broome RL, Omary MB. Keratin binding to 14-3-3 proteins modulates keratin filaments and hepatocyte mitotic progression. Proc Natl Acad Sci USA 2002; 99: 4373-4378.
31. Ku NO, Liao J, Omary MB. Phosphorylation of human keratin 18 serine 33 regulates binding to 14-3-3 proteins. EMBO J 1998; 17: 1892-1906.
32. Fan SQ, Ma J, Zhou J, Xiong W, Xiao BY, Zhang WL et al. Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis. Hum Pathol 2006; 37: 593-605.
33. Rodrigues L, Teixeira J, Schmitt F, Paulsson M, Mansson HL. Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr 2009; 49: 203-217.
34. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-7464.
35. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005; 24: 7391-7393.
36. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94: 851-857.
37. Zhang DH, Tai LK, Wong LL, Sethi SK, Koay ES. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Proteomics 2005; 5: 1797-1805.
38. Kippenberger S, Hofmann M, Zoller N, Thaci D, Muller J, Kaufmann R et al. Ligation of beta4 integrins activates PKB/Akt and ERK1/2 by distinct pathways-relevance of the keratin filament. Biochim Biophys Acta 2010; 1803: 940-950.
39. Eriksson JE, Dechat T, Grin B, Helfand B, Mendez M, Pallari HM et al. Introducing intermediate filaments: from discovery to disease. J Clin Invest 2009; 119: 1763-1771.
40. Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009; 19: 16-23.
41. Obsilova V, Silhan J, Boura E, Teisinger J, Obsil T. 14-3-3 proteins: a family of versatile molecular regulators. Physiol Res 2008; 57: S11-S21.
42. Darling DL, Yingling J, Wynshaw-Boris A. Role of 14-3-3 proteins in eukaryotic signaling and development. Curr Top Dev Biol 2005; 68: 281-315.
43. Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Bañ ez L et al. Silencing of Lactotransferrin expression by methylation in prostate cancer progression. Cancer Biol Ther 2007; 6: 1088-1095.
44. Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y et al. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci 2011; 124: 2997-3005.